priors.science/reviews/giant-cell-arteritis

Giant Cell Arteritis

The current evidence on 7 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

8claims tracked

7assessed

58primary papers reviewed

26 Oct 2026latest evidence review

2 Established · 5 Likely · 0 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

Glucocorticoid monotherapy relapses on taperGlucocorticoidEstablished87%8

Relapse common after tocilizumab discontinuationTocilizumabEstablished86%10

Large-vessel ultrasound adds sensitivityImagingLikely83%9

Tocilizumab sustains glucocorticoid-free remissionTocilizumabLikely80%8

Temporal artery halo sign diagnosticImagingLikely76%13

Upadacitinib induces remissionEmergingLikely74%8thin basis

Glucocorticoids reduce vision lossGlucocorticoidLikely73%10

Track Giant Cell Arteritis.

These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing: what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it. Confidently false as stated.

A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.